67.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NFLX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$67.85
Offen:
$67.6
24-Stunden-Volumen:
22.93M
Relative Volume:
0.62
Marktkapitalisierung:
$279.21B
Einnahmen:
$48.77B
Nettoeinkommen (Verlust:
$13.65B
KGV:
21.13
EPS:
3.1742
Netto-Cashflow:
$11.15B
1W Leistung:
-5.74%
1M Leistung:
-18.94%
6M Leistung:
-32.03%
1J Leistung:
-42.32%
Netflix Inc Stock (NFLX) Company Profile
Firmenname
Netflix Inc
Sektor
Branche
Telefon
408-540-3700
Adresse
121 ALBRIGHT WAY, LOS GATOS
Compare NFLX vs DIS, WBD, LYV, FOXA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
NFLX
Netflix Inc
|
67.06 | 296.24B | 48.77B | 13.65B | 11.15B | 3.1742 |
|
DIS
Walt Disney Co
|
102.36 | 183.29B | 97.37B | 12.34B | 7.11B | 6.2499 |
|
WBD
Warner Bros Discovery Inc
|
30.95 | 77.37B | 37.25B | -1.71B | 2.31B | -0.6988 |
|
LYV
Live Nation Entertainment Inc
|
169.33 | 39.81B | 25.61B | -229.57M | 1.21B | -1.7628 |
|
FOXA
Fox Corp
|
62.11 | 26.59B | 16.20B | 1.75B | 2.14B | 3.789 |
Netflix Inc Stock (NFLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Herabstufung | Erste Group | Buy → Hold |
| 2026-04-20 | Bestätigt | Bernstein | Outperform |
| 2026-04-06 | Hochstufung | Goldman | Neutral → Buy |
| 2026-03-30 | Eingeleitet | Citizens | Mkt Perform |
| 2026-03-24 | Hochstufung | Erste Group | Hold → Buy |
| 2026-03-18 | Fortgesetzt | Citigroup | Buy |
| 2026-03-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2026-03-02 | Fortgesetzt | Barclays | Equal Weight |
| 2026-03-02 | Fortgesetzt | JP Morgan | Overweight |
| 2026-02-27 | Hochstufung | Arete | Neutral → Buy |
| 2026-02-27 | Fortgesetzt | Evercore ISI | Outperform |
| 2026-01-23 | Bestätigt | Robert W. Baird | Outperform |
| 2026-01-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2026-01-21 | Bestätigt | Canaccord Genuity | Buy |
| 2026-01-21 | Bestätigt | Deutsche Bank | Hold |
| 2026-01-21 | Bestätigt | Goldman | Neutral |
| 2026-01-21 | Bestätigt | Guggenheim | Buy |
| 2026-01-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2026-01-21 | Bestätigt | Morgan Stanley | Overweight |
| 2026-01-21 | Bestätigt | Needham | Buy |
| 2026-01-21 | Bestätigt | Oppenheimer | Outperform |
| 2026-01-21 | Bestätigt | Piper Sandler | Overweight |
| 2026-01-21 | Bestätigt | Pivotal Research Group | Hold |
| 2026-01-21 | Bestätigt | Rosenblatt | Neutral |
| 2026-01-21 | Bestätigt | Rothschild & Co Redburn | Buy |
| 2026-01-21 | Bestätigt | TD Cowen | Buy |
| 2026-01-21 | Bestätigt | UBS | Buy |
| 2026-01-21 | Bestätigt | Wolfe Research | Outperform |
| 2026-01-12 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-09 | Bestätigt | Goldman | Neutral |
| 2025-12-08 | Herabstufung | Pivotal Research Group | Buy → Hold |
| 2025-12-08 | Herabstufung | Rosenblatt | Buy → Neutral |
| 2025-11-18 | Bestätigt | Barclays | Equal Weight |
| 2025-10-31 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-07 | Hochstufung | Seaport Research Partners | Neutral → Buy |
| 2025-09-17 | Hochstufung | Loop Capital | Hold → Buy |
| 2025-07-10 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-07-07 | Herabstufung | Seaport Research Partners | Buy → Neutral |
| 2025-07-02 | Bestätigt | Canaccord Genuity | Buy |
| 2025-07-02 | Bestätigt | Goldman | Neutral |
| 2025-06-20 | Bestätigt | Pivotal Research Group | Buy |
| 2025-06-12 | Bestätigt | Oppenheimer | Outperform |
| 2025-06-03 | Bestätigt | Jefferies | Buy |
| 2025-05-30 | Bestätigt | BofA Securities | Buy |
| 2025-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-04-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-04-21 | Bestätigt | Barclays | Equal Weight |
| 2025-04-21 | Bestätigt | Canaccord Genuity | Buy |
| 2025-04-21 | Bestätigt | Guggenheim | Buy |
| 2025-04-21 | Bestätigt | JP Morgan | Overweight |
| 2025-04-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2025-04-21 | Bestätigt | MoffettNathanson | Buy |
| 2025-04-21 | Bestätigt | Morgan Stanley | Overweight |
| 2025-04-21 | Bestätigt | Oppenheimer | Outperform |
| 2025-04-21 | Bestätigt | Piper Sandler | Overweight |
| 2025-04-21 | Bestätigt | Pivotal Research Group | Buy |
| 2025-04-21 | Bestätigt | Wells Fargo | Overweight |
| 2025-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-27 | Eingeleitet | FBN Securities | Outperform |
| 2025-03-17 | Hochstufung | MoffettNathanson | Neutral → Buy |
| 2025-01-24 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-01-23 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-01-22 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-01-22 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2025-01-22 | Bestätigt | Pivotal Research Group | Buy |
| 2025-01-22 | Hochstufung | Rosenblatt | Neutral → Buy |
| 2025-01-22 | Hochstufung | The Benchmark Company | Sell → Hold |
| 2025-01-16 | Hochstufung | Seaport Research Partners | Neutral → Buy |
| 2025-01-15 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-01-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-01-08 | Bestätigt | Goldman | Neutral |
| 2025-01-06 | Bestätigt | Argus | Buy |
| 2025-01-03 | Bestätigt | The Benchmark Company | Sell |
| 2024-12-19 | Bestätigt | UBS | Buy |
| 2024-12-16 | Herabstufung | Loop Capital | Buy → Hold |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-11 | Bestätigt | JP Morgan | Overweight |
| 2024-11-20 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-18 | Bestätigt | Needham | Buy |
| 2024-10-18 | Bestätigt | Oppenheimer | Outperform |
| 2024-10-18 | Bestätigt | Pivotal Research Group | Buy |
| 2024-10-16 | Bestätigt | Loop Capital | Buy |
| 2024-10-11 | Bestätigt | Guggenheim | Buy |
| 2024-10-10 | Bestätigt | Morgan Stanley | Overweight |
| 2024-10-10 | Bestätigt | Oppenheimer | Outperform |
| 2024-10-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-10-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-10-01 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-09-05 | Eingeleitet | China Renaissance | Hold |
| 2024-08-30 | Bestätigt | Pivotal Research Group | Buy |
| 2024-07-17 | Bestätigt | Guggenheim | Buy |
| 2024-07-16 | Bestätigt | The Benchmark Company | Sell |
| 2024-07-15 | Bestätigt | BofA Securities | Buy |
| 2024-07-12 | Bestätigt | JP Morgan | Overweight |
| 2024-07-10 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-07-09 | Bestätigt | TD Cowen | Buy |
| 2024-07-02 | Bestätigt | Argus | Buy |
| 2024-05-28 | Bestätigt | Evercore ISI | Outperform |
| 2024-04-19 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-04-19 | Hochstufung | Needham | Hold → Buy |
| 2024-04-19 | Bestätigt | Pivotal Research Group | Buy |
| 2024-04-15 | Bestätigt | Deutsche Bank | Hold |
| 2024-04-12 | Bestätigt | Morgan Stanley | Overweight |
| 2024-04-12 | Bestätigt | Piper Sandler | Neutral |
| 2024-04-05 | Bestätigt | Pivotal Research Group | Buy |
| 2024-03-25 | Bestätigt | Citigroup | Neutral |
| 2024-03-12 | Bestätigt | Jefferies | Buy |
| 2024-03-11 | Bestätigt | Oppenheimer | Outperform |
| 2024-01-30 | Herabstufung | Seaport Research Partners | Buy → Neutral |
| 2024-01-25 | Hochstufung | DZ Bank | Hold → Buy |
| 2024-01-24 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-01-24 | Bestätigt | BofA Securities | Buy |
| 2024-01-24 | Bestätigt | Canaccord Genuity | Buy |
| 2024-01-24 | Bestätigt | Evercore ISI | Outperform |
| 2024-01-24 | Bestätigt | Goldman | Neutral |
| 2024-01-24 | Bestätigt | Guggenheim | Buy |
| 2024-01-24 | Bestätigt | JP Morgan | Overweight |
| 2024-01-24 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2024-01-24 | Hochstufung | Macquarie | Neutral → Outperform |
| 2024-01-24 | Bestätigt | Morgan Stanley | Overweight |
| 2024-01-24 | Bestätigt | Oppenheimer | Outperform |
| 2024-01-24 | Bestätigt | Piper Sandler | Neutral |
| 2024-01-24 | Bestätigt | Pivotal Research Group | Buy |
| 2024-01-24 | Bestätigt | Redburn Atlantic | Buy |
| 2024-01-24 | Bestätigt | Robert W. Baird | Outperform |
| 2024-01-24 | Bestätigt | TD Cowen | Outperform |
| 2024-01-24 | Bestätigt | UBS | Buy |
| 2024-01-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-09-18 | Bestätigt | Evercore ISI | Outperform |
| 2023-08-25 | Hochstufung | Loop Capital | Hold → Buy |
| 2023-07-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-07-17 | Bestätigt | Deutsche Bank | Buy |
| 2023-07-13 | Bestätigt | JP Morgan | Overweight |
| 2023-07-12 | Bestätigt | UBS | Buy |
| 2023-07-05 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-29 | Bestätigt | Citigroup | Buy |
| 2023-06-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-06-13 | Bestätigt | BofA Securities | Buy |
| 2023-06-13 | Bestätigt | Guggenheim | Buy |
| 2023-04-19 | Bestätigt | Deutsche Bank | Buy |
| 2023-04-19 | Bestätigt | JP Morgan | Overweight |
| 2023-04-19 | Bestätigt | Jefferies | Buy |
| 2023-04-19 | Bestätigt | Piper Sandler | Neutral |
| 2023-04-19 | Bestätigt | Pivotal Research Group | Buy |
| 2023-04-19 | Bestätigt | Rosenblatt | Neutral |
| 2023-04-19 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-11 | Fortgesetzt | Robert W. Baird | Neutral |
| 2023-01-23 | Bestätigt | Argus | Buy |
| 2023-01-20 | Bestätigt | Canaccord Genuity | Buy |
| 2023-01-20 | Bestätigt | Deutsche Bank | Buy |
| 2023-01-20 | Bestätigt | Evercore ISI | Outperform |
| 2023-01-20 | Bestätigt | Goldman | Sell |
| 2023-01-20 | Bestätigt | Guggenheim | Buy |
| 2023-01-20 | Bestätigt | Jefferies | Buy |
| 2023-01-20 | Bestätigt | MoffettNathanson | Market Perform |
| 2023-01-20 | Bestätigt | Oppenheimer | Outperform |
| 2023-01-20 | Bestätigt | Piper Sandler | Neutral |
| 2023-01-20 | Bestätigt | Pivotal Research Group | Buy |
| 2023-01-20 | Bestätigt | Robert W. Baird | Neutral |
| 2023-01-20 | Bestätigt | The Benchmark Company | Sell |
| 2023-01-20 | Bestätigt | Wedbush | Outperform |
| 2023-01-20 | Bestätigt | Wolfe Research | Outperform |
| 2023-01-12 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-04 | Eingeleitet | New Street | Neutral |
| 2022-12-29 | Hochstufung | CFRA | Sell → Buy |
| 2022-12-14 | Bestätigt | Jefferies | Hold |
| 2022-12-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-06-14 | Herabstufung | The Benchmark Company | Hold → Sell |
| 2022-06-10 | Herabstufung | Goldman | Neutral → Sell |
| 2022-05-16 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-04-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-04-21 | Herabstufung | Edward Jones | Buy → Hold |
| 2022-04-20 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-04-20 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-04-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-04-20 | Hochstufung | Needham | Underperform → Hold |
| 2022-04-20 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Herabstufung | Pivotal Research Group | Buy → Sell |
| 2022-04-20 | Herabstufung | Stifel | Buy → Hold |
| 2022-04-20 | Herabstufung | UBS | Buy → Neutral |
| 2022-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-19 | Eingeleitet | Rosenblatt | Neutral |
| 2022-03-09 | Hochstufung | Wedbush | Underperform → Neutral |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Edward Jones | Hold → Buy |
| 2022-01-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-01-21 | Bestätigt | BofA Securities | Buy |
| 2022-01-21 | Bestätigt | Canaccord Genuity | Buy |
| 2022-01-21 | Bestätigt | Cowen | Outperform |
| 2022-01-21 | Bestätigt | Deutsche Bank | Hold |
| 2022-01-21 | Bestätigt | Goldman | Neutral |
| 2022-01-21 | Bestätigt | Guggenheim | Buy |
| 2022-01-21 | Bestätigt | JP Morgan | Overweight |
| 2022-01-21 | Bestätigt | MoffettNathanson | Neutral |
| 2022-01-21 | Herabstufung | Monness Crespi & Hardt | Buy → Neutral |
| 2022-01-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-21 | Bestätigt | Oppenheimer | Outperform |
| 2022-01-21 | Bestätigt | Piper Sandler | Overweight |
| 2022-01-21 | Bestätigt | Pivotal Research Group | Buy |
| 2022-01-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-01-21 | Bestätigt | Stifel | Buy |
| 2022-01-21 | Hochstufung | The Benchmark Company | Sell → Hold |
| 2022-01-21 | Herabstufung | Truist | Buy → Hold |
| 2022-01-21 | Bestätigt | UBS | Buy |
| 2022-01-21 | Bestätigt | Wolfe Research | Outperform |
| 2021-12-15 | Bestätigt | The Benchmark Company | Sell |
| 2021-10-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-10-20 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2021-09-29 | Bestätigt | The Benchmark Company | Sell |
| 2021-09-13 | Eingeleitet | Goldman | Neutral |
| 2021-09-08 | Bestätigt | JP Morgan | Overweight |
| 2021-09-07 | Bestätigt | Atlantic Equities | Overweight |
| 2021-07-21 | Bestätigt | Credit Suisse | Outperform |
| 2021-07-21 | Bestätigt | Deutsche Bank | Buy |
| 2021-07-21 | Bestätigt | JP Morgan | Overweight |
| 2021-07-21 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2021-07-21 | Bestätigt | Stifel | Buy |
| 2021-06-25 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-06-25 | Eingeleitet | Edward Jones | Hold |
| 2021-05-19 | Fortgesetzt | Jefferies | Buy |
| 2021-04-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-21 | Bestätigt | Pivotal Research Group | Buy |
| 2021-04-21 | Hochstufung | Stifel | Hold → Buy |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-04-01 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-25 | Bestätigt | The Benchmark Company | Sell |
| 2021-03-23 | Hochstufung | Argus | Hold → Buy |
| 2021-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-01-20 | Bestätigt | Monness Crespi & Hardt | Buy |
| 2021-01-20 | Bestätigt | Pivotal Research Group | Buy |
| 2021-01-20 | Bestätigt | The Benchmark Company | Sell |
| 2021-01-20 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-21 | Bestätigt | BMO Capital Markets | Outperform |
| 2020-10-21 | Bestätigt | Bernstein | Outperform |
| 2020-10-21 | Bestätigt | Jefferies | Buy |
| 2020-10-21 | Bestätigt | Morgan Stanley | Overweight |
| 2020-10-21 | Bestätigt | Oppenheimer | Outperform |
| 2020-10-21 | Bestätigt | Piper Sandler | Overweight |
| 2020-10-21 | Bestätigt | Pivotal Research Group | Buy |
| 2020-10-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-10-21 | Bestätigt | The Benchmark Company | Sell |
| 2020-10-21 | Bestätigt | Wedbush | Underperform |
| 2020-10-21 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-10-16 | Bestätigt | Morgan Stanley | Overweight |
| 2020-10-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-10-14 | Bestätigt | Goldman | Buy |
| 2020-10-07 | Bestätigt | Pivotal Research Group | Buy |
| 2020-09-28 | Bestätigt | The Benchmark Company | Sell |
| 2020-09-15 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-09 | Fortgesetzt | Raymond James | Mkt Perform |
| 2020-09-04 | Bestätigt | The Benchmark Company | Sell |
| 2020-07-29 | Bestätigt | Loop Capital | Buy |
Alle ansehen
Netflix Inc Aktie (NFLX) Neueste Nachrichten
Netflix Eyes Theaters for ‘KPop Demon Hunters 2’Netflix (NASDAQ:NFLX) - Benzinga
Naomi Bulochnikov-Paul to Lead Series Comms at Netflix - IMDb
Netflix Has Chased the Best Picture Oscar for Nearly a Decade. Can ‘La Bola Negra’ Finally Win It for the Streamer? - IMDb
Netflix Hires Former Disney Exec Naomi Bulochnikov-Paul as Head of TV Series Communications - IMDb
Disney’s Naomi Bulochnikov-Paul Jumps to Netflix as VP of Series Comms - IMDb
Netflix Loses 'Stranger Things' Creative To Disney in Major Television Deal - IMDb
Ted Sarandos Explains Why the ‘Stranger Things’ Team Left Netflix - The Hollywood Reporter
Rebecca Lowe Joins Netflix’s Broadcast Team for FIFA Women’s World Cup 2027 - IMDb
Netflix, Inc. $NFLX Stock Holdings Reduced by Coastline Trust Co - MarketBeat
Netflix Co-CEO's Growth Concerns Spark Market Reaction, NFLX Dow - GuruFocus
Netflix co-CEO says streaming giant "isn't growing as fast as I want us to" - Proactive financial news
After a Lengthy Slide, It May Be Time to Tune Into a Netflix ETF - ETF Database
Netflix (NASDAQ:NFLX) Stacks Slate With Live Sports - Kalkine Media
Netflix Nabs ‘American Royals’ YA Drama From ‘Red, White & Royal Blue’ Co-Writer Ted Malawer & Alloy Based On Books - IMDb
Ben Affleck used AI ‘for lots of things’ in upcoming Netflix movie - NewsNation
Netflix's Biggest Movie of All Time Set for Major Sequel Shake-Up as Release Strategy Is Confirmed - MovieWeb
Amelia Dimoldenberg to Bring ‘Chicken Shop Date’ Final Season to Netflix and YouTube (EXCLUSIVE) - variety.com
Netflix CEO Says Company’s Growth Not Good Enough: What's Next?Netflix (NASDAQ:NFLX) - Benzinga
Netflix CEO Makes Blunt Admission on Growth - TradingView
Netflix: Decoding The Threat Posed By YouTube (NASDAQ:NFLX) - Seeking Alpha
Ben Affleck Reveals His New Netflix Thriller Movie Uses AI ‘For Lots of Things’ - yahoo.com
Netflix's CEO Just Admitted Growth Isn't Moving Fast Enough - TradingView
East of Eden on Netflix ending, explained: Who dies and how? - netflixlife.com
Ben Affleck Tries to Address Matt Damon's Comments About Making Netflix Action Movies, Admits Using AI for 'Lots of Things' in His New Film - ign.com
Why Is Netflix (NASDAQ:NFLX) Suddenly a Must-Watch Communication Stocks Stock Today? - Kalkine Media
Market movers: Accenture, Micron, Netflix, Nine Mile Metals... - Proactive financial news
Guggenheim raises Netflix stock price target to $80 on valuation By Investing.com - Investing.com Canada
Deutsche Bank upgrades Netflix stock to Buy despite lower target - AD HOC NEWS
Guggenheim raises Netflix stock price target to $80 on valuation - Investing.com
Netflix at Crossroads: Compressed Valuation, Weak Techs - TradingPedia
Netflix’s Problem Isn’t Subscribers, It’s Losing the Attention War - Barchart.com
Netflix CEO Sounds Warning on Growth: 'Not Growing as Fast as I Want' - Yahoo Finance
Guggenheim Adjusts Price Target on Netflix to $80 From $75, Keeps Buy Rating - marketscreener.com
WWE's Netflix Censors Are At It AGAIN (WWE News) - Yahoo Sports
If I Had $10,000 to Invest Today, Here's the Growth Stock I'd Buy Instead of SpaceX - The Motley Fool
Florence Pugh’s Netflix Adaptation Has a New Take on the Question of Where Do Monsters Come From - ign.com
Netflix Co-CEO Voices Growth Concerns Amid Live Content Challenges, NFLX Stock Shows Deep Undervaluation - GuruFocus
Ted Sarandos Has No Regrets Over WB, Talks Overall Deals & Casey Bloys - Deadline
Netflix Co-CEO Sarandos says growth slower than desired, touts live content (NFLX:NASDAQ) - Seeking Alpha
Ben Affleck Used AI “For Lots of Things” in His New Netflix Movie ‘Animals’ - The Hollywood Reporter
Netflix’s Growth Pace Isn’t Meeting Ted Sarandos’ Ambitions - Yahoo Finance
Netflix Stock Drops 40% as Movie Theaters Surge on Blockbusters - 조선일보
Netflix ‘Not Growing as Fast as I Want,’ Co-CEO Sarandos Says - Bloomberg.com
Ted Sarandos Admits Netflix Is "Not Growing as Fast as I Want Us To" - The Hollywood Reporter
How Much Do You Need to Have Netflix, Disney and the 8 Major Streaming Platforms? - Yahoo Finance
Wall Street bank backs Netflix despite U.S. drift to YouTube - Yahoo Finance
Netflix (NASDAQ:NFLX) Stock Price Down 1%Should You Sell? - MarketBeat
Netflix Stock Has Turned $1,000 Into About $654,000 Since Its IPO. It Has Gone Nowhere Since 2021. - Yahoo Finance
Netflix's Content Commitments Rise: Is Cash Flow Under Pressure? - TradingView
What You Need To Know Ahead of Netflix's Earnings Release - Barchart.com
Netflix: 50% Down From All-Time Highs, But Don’t Think Recovery Is Guaranteed Yet (NFLX) - Seeking Alpha
Finanzdaten der Netflix Inc-Aktie (NFLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Netflix Inc-Aktie (NFLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BARTON RICHARD N | Director |
Sep 09 '26 |
Option Exercise |
24.46 |
720 |
17,613 |
3,180 |
| BARTON RICHARD N | Director |
Sep 09 '26 |
Sale |
76.26 |
720 |
54,907 |
2,460 |
| BARTON RICHARD N | Director |
Sep 10 '26 |
Sale |
75.27 |
720 |
54,194 |
2,460 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):